MedTrace Logo

DP-b99 in the Treatment of Acute High-risk Pancreatitis

NCT02025049 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-06-23

No results posted yet for this study

Summary

Inflammation of the pancreas often leads to severe damage not only to the pancreas but also to other organs in the abdomen as well as to complications in organs further away like the lung and the kidney. This trial will examine if DP-b99, given to patients with non-severe inflammation of the pancreas, can mitigate the development of processes that can lead to serious complications of this disease.

Conditions

Interventions

DRUG

DP-b99

DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)

DRUG

Placebo

mannitol-based DP-b99 look-alike

Sponsors & Collaborators

  • D-Pharm Ltd.

    lead INDUSTRY

Principal Investigators

  • Gilad Rosenberg, MD · D-Pharm Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02025049 on ClinicalTrials.gov